Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Fruquintinib in HER2+ Advanced CRC
NCT05661357Phase 4Active, not recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of disitamab vedotin in colorectal cancer (CRC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05661357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661357.